FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200417924> ?p ?o ?g. }

• W4200417924 abstract "Abstract BackgroundGlobally rifampicin-resistant tuberculosis disease affects around 460 000 people each year. Current recommended regimens are 9-24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. MethodsTB-PRACTECAL is an open-label, randomised, controlled, phase II/III non-inferiority trial evaluating the safety and efficacy of 24 week regimens containing bedaquiline and pretomanid to treat rifampicin resistant tuberculosis. Conducted in Uzbekistan, South Africa and Belarus, patients aged 15 and above with rifampicin resistant pulmonary tuberculosis and requiring a new course of therapy are eligible for inclusion irrespective of HIV status. In the first stage, equivalent to a phase IIB trial, patients are randomly assigned one of four regimens, stratified by site. Investigational regimens include oral bedaquiline, pretomanid and linezolid. Additionally, two of the regimens also include moxifloxacin (arm 1) and clofazimine (arm 2) respectively. Treatment is administered under direct observation for 24 weeks in investigational arms and 36 to 96 weeks in the standard of care arm. The second stage of the study is equivalent to a phase III trial, investigating the safety and efficacy of the most promising regimen/s. The primary outcome is the percentage of unfavourable outcomes at 72 weeks post randomisation. This is a composite of early treatment discontinuation, treatment failure, recurrence, lost to follow up and death. The study is conducted in accordance with ICH-GCP and full ethical approval was obtained from Médecins sans Frontières ethical review board, London School of Hygiene and Tropical Medicine ethical review board as well as ERBs and regulatory authorities at each site. DiscussionTB-PRACTECAL is an ambitious trial using adaptive design to accelerate regimen assessment and bring novel regimens that are effective and safe to patients quicker. The trial took a patient-centred approach, adapting to best practice guidelines throughout recruitment. The implementation faced significant challenges from the COVID-19 pandemic. The trial was terminated early for efficacy on the advice of the DSMB and will report on data collected up to end of recruitment and additionally, the planned final analysis at 72 weeks after end of recruitment. Trial registrationClinicaltrials.gov registration number NCT02589782" @default.
• W4200417924 created "2021-12-31" @default.
• W4200417924 creator A5025450803 @default.
• W4200417924 creator A5026823919 @default.
• W4200417924 creator A5032443247 @default.
• W4200417924 creator A5048349468 @default.
• W4200417924 creator A5052878399 @default.
• W4200417924 creator A5060911998 @default.
• W4200417924 creator A5071807728 @default.
• W4200417924 creator A5076621207 @default.
• W4200417924 creator A5084398948 @default.
• W4200417924 creator A5089116964 @default.
• W4200417924 date "2021-12-14" @default.
• W4200417924 modified "2023-09-27" @default.
• W4200417924 title "Tb-practecal: Study Protocol for a Randomised, Controlled, Open-label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis" @default.
• W4200417924 doi "https://doi.org/10.21203/rs.3.rs-992464/v1" @default.
• W4200417924 hasPublicationYear "2021" @default.
• W4200417924 type Work @default.
• W4200417924 citedByCount "0" @default.
• W4200417924 crossrefType "posted-content" @default.
• W4200417924 hasAuthorship W4200417924A5025450803 @default.
• W4200417924 hasAuthorship W4200417924A5026823919 @default.
• W4200417924 hasAuthorship W4200417924A5032443247 @default.
• W4200417924 hasAuthorship W4200417924A5048349468 @default.
• W4200417924 hasAuthorship W4200417924A5052878399 @default.
• W4200417924 hasAuthorship W4200417924A5060911998 @default.
• W4200417924 hasAuthorship W4200417924A5071807728 @default.
• W4200417924 hasAuthorship W4200417924A5076621207 @default.
• W4200417924 hasAuthorship W4200417924A5084398948 @default.
• W4200417924 hasAuthorship W4200417924A5089116964 @default.
• W4200417924 hasBestOaLocation W42004179241 @default.
• W4200417924 hasConcept C126322002 @default.
• W4200417924 hasConcept C141071460 @default.
• W4200417924 hasConcept C142724271 @default.
• W4200417924 hasConcept C203014093 @default.
• W4200417924 hasConcept C2776297342 @default.
• W4200417924 hasConcept C2777975735 @default.
• W4200417924 hasConcept C2778607973 @default.
• W4200417924 hasConcept C2778715236 @default.
• W4200417924 hasConcept C2778836808 @default.
• W4200417924 hasConcept C2780544761 @default.
• W4200417924 hasConcept C2780695269 @default.
• W4200417924 hasConcept C2781069245 @default.
• W4200417924 hasConcept C2781413609 @default.
• W4200417924 hasConcept C501593827 @default.
• W4200417924 hasConcept C71924100 @default.
• W4200417924 hasConcept C86803240 @default.
• W4200417924 hasConcept C89423630 @default.
• W4200417924 hasConceptScore W4200417924C126322002 @default.
• W4200417924 hasConceptScore W4200417924C141071460 @default.
• W4200417924 hasConceptScore W4200417924C142724271 @default.
• W4200417924 hasConceptScore W4200417924C203014093 @default.
• W4200417924 hasConceptScore W4200417924C2776297342 @default.
• W4200417924 hasConceptScore W4200417924C2777975735 @default.
• W4200417924 hasConceptScore W4200417924C2778607973 @default.
• W4200417924 hasConceptScore W4200417924C2778715236 @default.
• W4200417924 hasConceptScore W4200417924C2778836808 @default.
• W4200417924 hasConceptScore W4200417924C2780544761 @default.
• W4200417924 hasConceptScore W4200417924C2780695269 @default.
• W4200417924 hasConceptScore W4200417924C2781069245 @default.
• W4200417924 hasConceptScore W4200417924C2781413609 @default.
• W4200417924 hasConceptScore W4200417924C501593827 @default.
• W4200417924 hasConceptScore W4200417924C71924100 @default.
• W4200417924 hasConceptScore W4200417924C86803240 @default.
• W4200417924 hasConceptScore W4200417924C89423630 @default.
• W4200417924 hasLocation W42004179241 @default.
• W4200417924 hasLocation W42004179242 @default.
• W4200417924 hasLocation W42004179243 @default.
• W4200417924 hasLocation W42004179244 @default.
• W4200417924 hasLocation W42004179245 @default.
• W4200417924 hasOpenAccess W4200417924 @default.
• W4200417924 hasPrimaryLocation W42004179241 @default.
• W4200417924 hasRelatedWork W2744335668 @default.
• W4200417924 hasRelatedWork W2792244370 @default.
• W4200417924 hasRelatedWork W2973028036 @default.
• W4200417924 hasRelatedWork W2981229088 @default.
• W4200417924 hasRelatedWork W3005026892 @default.
• W4200417924 hasRelatedWork W3196232496 @default.
• W4200417924 hasRelatedWork W4200417924 @default.
• W4200417924 hasRelatedWork W4282566830 @default.
• W4200417924 hasRelatedWork W4308928968 @default.
• W4200417924 hasRelatedWork W4362693120 @default.
• W4200417924 isParatext "false" @default.
• W4200417924 isRetracted "false" @default.
• W4200417924 workType "article" @default.